A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

NCT06503614 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer
Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Monalizumab

Sponsor

John Sfakianos

Collaborators

[object Object]
[object Object]
[object Object]